Indicators of hemostasis and fibrinolysis systems and systemic inflammatory response in patients with newly diagnosed sarcoidosis after COVID-19

Author:

Abdullaev R.1,Shorokhova V.1,Makaryants N.1,Komissarova O.1

Affiliation:

1. Central Research Institute of Tuberculosis, Moscow

Abstract

Objective. To study the indicators of hemostasis and fibrinolysis systems, as well as the systemic inflammatory response in patients with newly diagnosed sarcoidosis after infection caused by SARS-CoV-2. Material and methods. A prospective analysis of the indicators of hemostasis and fibrinolysis systems, as well as the systemic inflammatory response of 20 patients with sarcoidosis, after COVID-19, who were on inpatient treatment in Central TB Research Institute. The patients were divided into 2 groups. The first group included 10 patients with sarcoidosis, who had suffered COVID-19 (the main group). The comparison group consisted of 10 patients with sarcoidosis without a history of COVID-19. Results. It was found, that in patients with newly diagnosed sarcoidosis, who underwent COVID-19, there is a hypercoagulation shift in the hemostasis and fibrinolysis system. This was evidenced by a significant shortening of the indicators of APTT, PT and an increase in the level of D-dimer compared to both healthy and patients, who had not undergone COVID-19. In addition, laboratory manifestations of systemic inflammation were most pronounced in patients with sarcoidosis who underwent COVID-19. Probably, changes in the hemostasis and fibrinolysis system occurred within the framework of a systemic inflammatory response.

Publisher

Russian Vrach, Publishing House Ltd.

Reference15 articles.

1. Абдуллаев Р.Ю., Комиссарова О.Г. Лабораторные проявления короновирусной инфекции COVID-19. Врач. 2020; 31 (5): 3–6 [Abdullaev R., Komissarova O. Laboratory indicators of coronаvirus infection COVID-19. Vrach. 2020; 31 (5): 3–6. (in Russ.)]. DOI: 10.29296/25877305-2020-05-01

2. Бородулина Е.А., Широбоков Я.Е., Гладунова Е.П. и др. Диагностика и фармакотерапия вирус-ассоциированных поражений легких. Клиническая фармакология и терапия. 2020; 29 (3): 61–6 [Borodulina E.A., Shirobokov Y.E., Gladunova E.P. et al. Virus-associated lung disease. Clin Pharmacol Ther. 2020; 29 (3): 61–6 (in Russ.)]. DOI: 10.32756/0869-5490-2020-3-61-66

3. Визель А.А., Визель И.Ю., Амиров Н.Б. Эпидемиология саркоидоза в Российской Федерации. Вестник современной клинической медицины. 2017; 10 (5): 66–73 [Vizel А.А., Vizel I.Yu., Amirov N.B. Epidemiology of sarcoidosis in the Russian Federation. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 66–73 (in Russ.)]. DOI: 10.20969/VSKM.2017.10(5).66-73

4. Старшинова А.А., Малкова А.М., Зинченко Ю.С. и др. Аутоиммунная составляющая в этиологии саркоидоза. Туберкулез и болезни легких. 2020; 98(5): 54–62 [Starshinova A.A., Malkova A.M., Zinchenko Yu.S., et al. Autoimmune component in the etiology of sarcoidosis. Tuberculosis and Lung Diseases. 2020; 98 (5): 54–62 (in Russ.)]. DOI: 10.21292/2075-1230-2020-98-5-54-62

5. Brito-Zerón P., Gracia-Tello B., Robles A. et al. Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. Viruses. 2021; 13 (6): 1000. DOI: 10.3390/v13061000

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3